{"id":22065,"date":"2023-11-15T07:41:37","date_gmt":"2023-11-15T12:41:37","guid":{"rendered":"https:\/\/medicarereport.org\/?p=22065"},"modified":"2023-11-15T07:41:38","modified_gmt":"2023-11-15T12:41:38","slug":"biden-administrations-limit-on-drug-industry-middlemen-backfires-pharmacists-say","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=22065","title":{"rendered":"Biden Administration\u2019s Limit on Drug Industry Middlemen Backfires, Pharmacists Say"},"content":{"rendered":"\n

(By Arthur Allen for KFF Health News)<\/p>\n\n\n\n

The Biden administration\u2019s first major step toward imposing limits on the pharmacy benefit managers who act as the drug industry\u2019s price negotiators is backfiring, pharmacists say. Instead, it\u2019s adding to the woes of the independent drugstores it was partly designed to help.<\/p>\n\n\n\n

The so-called PBMs have long clawed back a fee from pharmacies weeks or months after they dispense a drug. A new rule, which governs Medicare\u2019s drug program, is set to take effect Jan. 1 and requires PBMs to take most of their \u201cperformance fees\u201d at the time prescriptions are filled. Continue reading here…<\/a><\/p>\n\n\n\n

Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J Kaiser Family Foundation.<\/p>\n\n\n\n

\"\"<\/p>\n\n\n\n

Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/p>\n","protected":false},"excerpt":{"rendered":"

(By Arthur Allen for KFF Health News) The Biden administration\u2019s first major step toward imposing limits on the pharmacy benefit<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32,21,20,10,6,15],"tags":[966,80,385,61,65,425,967],"class_list":["post-22065","post","type-post","status-publish","format-standard","hentry","category-cms","category-health-care-finance","category-health-care-redesign","category-legislative-update","category-medicare-general","category-part-dprescription-drugs","tag-clawed-back-fee","tag-cms","tag-healthcare-costs","tag-medicare","tag-medicare-part-d","tag-pbm-industry","tag-performance-fees"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/22065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22065"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/22065\/revisions"}],"predecessor-version":[{"id":22066,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/22065\/revisions\/22066"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}